AR052191A1 - TREATMENT METHOD - Google Patents

TREATMENT METHOD

Info

Publication number
AR052191A1
AR052191A1 ARP060100058A ARP060100058A AR052191A1 AR 052191 A1 AR052191 A1 AR 052191A1 AR P060100058 A ARP060100058 A AR P060100058A AR P060100058 A ARP060100058 A AR P060100058A AR 052191 A1 AR052191 A1 AR 052191A1
Authority
AR
Argentina
Prior art keywords
disorders
related disorders
substance
pharmaceutically acceptable
limited
Prior art date
Application number
ARP060100058A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR052191A1 publication Critical patent/AR052191A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para tratar al menos un síntoma o afeccion asociado con, aunque sin limitarse a: 1) Trastornos relacionados con sustancias incluyendo aunque sin limitarse a Dependencia de Sustancias, Abuso de Sustancias, Intoxicacion por Sustancias, Abstinencia de Sustancias, Trastornos Relacionados con el Alcohol, Trastornos Relacionados con Anfetaminas ( o Tipo Anfetaminas), Trastornos Relacionados con la Cafeína, Trastornos Relacionados con el Cannabis, Trastornos Relacionados con la Cocaína, Trastornos Relacionados con Alucinogenos, Trastornos relacionados con Inhalantes, Trastornos relacionados con la Nicotina, Trastornos relacionados con Opioides, Trastornos relacionados con Fenciclidina ( o del Tipo de la Fenciclidina) y Trastornos relacionados con Sedantes, Hipnoticos o Ansiolíticos; 2) Trastornos de Déficit de Atencion y Comportamiento Disruptivo; 3) Trastornos de la Alimentacion; 4) Trastornos de Personalidad que incluyen, aunque sin limitarse a Trastorno de la Personalidad Obsesivo-Compulsivo; 5) Trastornos de Control de Impulsos, que comprende la administracion de una cantidad eficaz de formula (1) o su sal farmacéuticamente aceptable. En otro aspecto de la presente se proporciona una composicion farmacéutica que comprende una cantidad eficaz de formula (1) o su sal farmacéuticamente aceptable y por lo menos un portador o diluyente farmacéuticamente aceptable.A method to treat at least one symptom or condition associated with, but not limited to: 1) Substance-related disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Abstinence, Alcohol Related Disorders , Amphetamine Related Disorders (or Amphetamine Type), Caffeine Related Disorders, Cannabis Related Disorders, Cocaine Related Disorders, Halluinogen Related Disorders, Inhalant Related Disorders, Nicotine Related Disorders, Opioid Related Disorders, Disorders related to Phencyclidine (or Phencyclidine Type) and Disorders related to Sedatives, Hypnotics or Anxiolytics; 2) Attention Deficit Disorders and Disruptive Behavior Disorders; 3) Eating Disorders; 4) Personality Disorders that include, but are not limited to Obsessive-Compulsive Personality Disorder; 5) Impulse Control Disorders, which comprises the administration of an effective amount of formula (1) or its pharmaceutically acceptable salt. In another aspect of the present there is provided a pharmaceutical composition comprising an effective amount of formula (1) or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

ARP060100058A 2005-01-07 2006-01-06 TREATMENT METHOD AR052191A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR052191A1 true AR052191A1 (en) 2007-03-07

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100058A AR052191A1 (en) 2005-01-07 2006-01-06 TREATMENT METHOD

Country Status (6)

Country Link
EP (1) EP1838325A1 (en)
JP (1) JP2008526839A (en)
AR (1) AR052191A1 (en)
TW (1) TW200640466A (en)
UY (1) UY29326A1 (en)
WO (1) WO2006073360A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
PT2307389E (en) 2008-06-20 2013-03-28 Astrazeneca Ab Dibenzothiazepine derivative and use thereof
US8389716B2 (en) 2009-01-30 2013-03-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of quetiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (en) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
EP1359919B1 (en) * 2001-02-06 2007-04-25 AstraZeneca AB Use of quetiapine for the treatment of cocaine dependence
EP1578428A4 (en) * 2002-10-18 2008-11-26 Massachusetts Mental Health In Treating alcohol and or substance abuse by antagonizing alpha a2 drenergic receptors with weak dopamine blocking
KR20060082037A (en) * 2003-07-02 2006-07-14 아스트라제네카 아베 Metabolite of quetiapine
AU2004294348A1 (en) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
UY29326A1 (en) 2006-08-31
JP2008526839A (en) 2008-07-24
TW200640466A (en) 2006-12-01
WO2006073360A1 (en) 2006-07-13
EP1838325A1 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
Bhutada et al. Reversal by quercetin of corticotrophin releasing factor induced anxiety-and depression-like effect in mice
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
BR0210711A (en) Use of a compound, pharmaceutical composition, compound, and process for preparing a compound
BRPI0607017B8 (en) pharmaceutical composition comprising memantine and donezepil, and their use for the treatment of snc-related conditions
BRPI0519181A2 (en) compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing a b-raf inhibitory effect on a warm-blooded animal to produce an anti-cancer effect on a warm-blooded animal and to treat a disease in a warm-blooded animal
ATE551060T1 (en) COMPOSITIONS AND METHODS FOR TREATING NEOVASCULAR DISEASES
BRPI0417959A (en) antibody or functional fragment thereof, pharmaceutical composition, method for treating or prophylaxis of stroke and other neurological disorders / disorders in a human, use of an anti-goat antibody, and methods for inhibiting neurodegeneration and / or promoting recovery function in a human patient, to promote axonal growth, to produce an antifungal antibody and to produce an intravenously administered pharmaceutical composition
AR065120A1 (en) COMPOUND OF ARIL PIRAZOL AZOESPIRODECANONA, ITS USE FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITION
BRPI0411906A (en) compounds, process for their preparation, pharmaceutical compositions comprising them, method for treating or preventing a disease mediated by activation of the glycogen synthase enzyme, and use of the compounds
BR0317358A (en) Pyrrolopyridazine compound, process for its preparation, pharmaceutical composition containing same, method of prevention or treatment of diseases containing same and their use
BRPI0511874A (en) pyrrolopyridine derivatives
BRPI0414428A (en) pharmaceutical compositions
AR062068A1 (en) TARTRATO SALT OF (7) S-7 - [(5-FLUORO-2-METHYL-BENCIL) OXI] -2 - [(2R) -2-METHYLPIPERAZIN-IL] -6,7-DIHYDRO-5H-CYCLOPENTA [B ] PIRIDINE, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USES IN ASSOCIATED DISORDERS FUNDAMENTALLY TO THE SCN
BRPI0418099A (en) compounds, pharmaceutical composition, and use of a compound
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
Martin Therapeutic potential of KELEA activated water
Ebrahimzadeh et al. Anticonvulsant activity of Hypericum scabrum L.; possible mechanism involved
Devi Milk thistle (Silybum marianum)
BRPI0409796A (en) use of dipyridamole or mopidamole for treatment and prevention of thromboembolic disorders and disorders caused by excessive thrombin formation and / or elevated expression of thrombin receptors
AR052191A1 (en) TREATMENT METHOD
Chiarini et al. “Other Than NLRP3” Inflammasomes: multiple roles in brain disease
Segura-Aguilar et al. Neurotoxins and neurotoxicity mechanisms. An overview
Guo et al. M9, a novel region of amino‐Nogo‐A, attenuates cerebral ischemic injury by inhibiting NADPH oxidase‐derived superoxide production in mice
Morshedi et al. The effect of artemisia sieberi besser on infkammatory and neurogenic pain in mice
GT200400068A (en) DERIVATIVES OF 3-AZABICICLO [3.2.1] OCTANO

Legal Events

Date Code Title Description
FA Abandonment or withdrawal